Two ‘Best Stocks’ are pulling back from highs. Josh Brown on how to trade them from here

Josh Brown and Sean Russo break down what’s going on with these stocks.

Skip NavigationJoin ICJoin ProLivestreamMenu(This is The Best Stocks in the Market , brought to you by Josh Brown and Sean Russo of Ritholtz Wealth Management.) Josh — Last week, we wrote up a few tech names that had been washed out of the list based on our risk management levels at the time of our original write-up. The purpose of our The Best Stocks in the Market column is to show you winning trade ideas that you might not otherwise be paying attention to. We’re trying to shine a light on these stories while simultaneously putting the fundamentals and technicals front and center. For obvious reasons, they don’t all work and things change. Sometimes we’ll lose a Best Stock from the list because of a market-wide sell-off we could not possibly foresee. Other times, there may be something specific happening in a sector or a theme that wrecks a beautiful chart. And in other instances, the story behind a previously winning ticker simply changes — or the sentiment around that story changes. This can happen based on a breaking news item or for no apparent reason at all. This is why stops and levels are a part of everything we write. Trading is not a game of batting averages (how many you get right or wrong). It’s about riding the ones you got right and not being blown up by the ones that turn against you. Anyone who says otherwise has never done this professionally and is only LARPing on the internet. In real life, you’re going to have stocks that don’t work all the time. The goal is to keep these temporary setbacks manageable and survivable, not to pretend you can avoid them entirely. With that bit of throat-clearing out of the way, today’s column looks at two Best Stocks that are now in pullbacks from their highs, Moderna (MRNA) and Delta (DAL) . Some of you have taken these trades from us so we’re going to give you an update. If you’re newer to the column, this will be an instructive look at how we adjust as time goes by. I was lucky enough to be in the audience a week ago when Dr. Stephen Hoge — one of the first 15 employees of Moderna and now its president — spoke at Baron Capital’s annual event at New York City’s Metropolitan Opera House in Lincoln Center. Dr. Hoge’s overarching theme was about how MRNA had been thought of as a Covid-19 vaccine maker but its true ambition is to provide personalized medicine formulations for millions of patients, custom-designed for each person’s specific genetic makeup and the diseases they’re struggling with or prone to. It is advancing the science with every passing day and the company’s capabilities in oncology are now the main story for why the stock is rallying. Delta is a stock I own personally and it’s been on, off and back on the list this year due to the ups and downs of oil prices more than for any other reason. I’ve got a stop in, but I’m hoping it doesn’t trigger because the business is doing incredibly well. DAL has been hanging high despite the pattern of lower highs since its July peak. We’ll talk about it. Before we do Moderna and Delta, Sean’s going to give you our usual Monday top-down look at the list itself. I’ll be back with the charts at the end. As of Nov. 16, there are 175 names on The Best Stocks in the Market list. Top sector ranking: Top industries: Top 5 best stocks by relative strength: Spotlight: Best Stocks — new additions & MRNA Moderna, Inc. (MRNA): Sean — Moderna has been on The Best Stocks in the Market list since June 26. We briefly mentioned it after the massive gap in August when the stock was up over 170% in a day after positive mRNA testing. Since joining the list at $67.27, shares are up 244%. This thing has been on a run. On Aug. 19, Moderna and Merck reported that their personalized cancer vaccine, intismeran, paired with Keytruda, cut the risk of melanoma recurrence or death by 42% in a Phase 3 trial. The stock went from $62.96 to $174.38 that day, a 177% gain, and it has added another 33% since, moving higher with most of healthcare. The fundamentals are starting to show up too. Q3 revenue grew 29% to $1.31 billion, and Moderna swung to a 38 cent-per-share profit from a 51 cent-per-share loss a year ago. Management raised 2026 revenue growth guidance to 15%-25% from “up to 10%,” with the midpoint implying about $2.3 billion. They also cut 2026 cash costs to roughly $3.8 billion, $200 million below prior guidance, and expect to finish the year with $8.1 billion-$8.3 billion in cash and investments. At Thursday’s Analyst Day, management reiterated plans to file intismeran (the blockbuster drug from earlier this summer) in 2026 for a potential 2027 launch. They guided this year’s gross margin to about 65%, excluding a $900 million litigation charge, up from 55% in 2025. They also cautioned that 15%-25% growth in the vaccine business shouldn’t be the planning assumption going forward. The stock fell 7% that day in response. Risk management: Josh — Moderna gapped out of its summer base on Aug. 19, opening at $116 after closing at $63 the day before, on the heaviest volume of the year. That’s a breakaway gap, and the cancer vaccine news Sean laid out above is the reason. It has never been filled, though at 48% below the stock it’s too far away to work as a stop now. The stock ran to $281 on Nov. 9, then gave back 17% from that day’s close in four sessions to Friday’s close at $223. The 50-day is rising at $202 and the 200-day is at $96. The $281 high is the level to clear. RSI is 50. Each new closing high since Oct. 15 came with a lower reading, RSI at 72, then 69, then 67 on Nov. 9. Price kept climbing with a little less force each time. The pullback has cleared that out. The Oct. 22 drop did the same thing, took RSI to 51, and buyers showed up at $180 within days. Anyone who wanted out of this move has had a chance. Traders can use $202 as their stop. That’s the rising 50-day, and the Oct. 13 and Oct. 28 lows both landed within a point or two of it. That’s not an accident. For anyone holding a big gain from the summer, a close below it is where you lock in most of it, because the pullback has become something more than a pullback. Investors can anchor to $180. The stock made its lows there twice, on Oct. 22 and again on Oct. 27, and held both times. A weekly close below it and the whole November advance has been given back. Delta Air Lines, Inc. (DAL): Sean — Delta is back on the list. We first wrote about DAL last December at $67.10, and it’s up 29% since. It fell off the list in March after the U.S.-Iran war began and sent oil higher, came back in May, and we mentioned it again in July at $87.39. It’s down 1% since then as DAL slid 20% from its June 30 high of $93.66 to $74.63 in late October, the day it came off the list a second time. It then rallied 24% to rejoin the list on Nov. 10 as oil pulled back. The fuel sensitivity cuts both ways. The whipsaws are thanks to fuel costs, but it’s important to note top line performance has not slowed down. Delta reported Q3 earnings on Oct. 9 with record adjusted revenue of $17.6 billion, up 16% on flat plane capacity. Adjusted EPS was $1.72 versus $1.70 a year ago, even with adjusted fuel expense up 62% to $4.1 billion. Premium and loyalty revenue each grew 18% year over year. For Q4, management guided revenue growth near 20% and EPS of $1.15-$1.65, assuming fuel at about $4.25 a gallon. Full-year guidance calls for EPS of $5.10-$5.60, about $2.5 billion of free cash flow and more than $2 billion of debt paydown, all while absorbing a $6 billion year over year increase in fuel costs. At the midpoint, DAL trades at about 16x this year’s earnings, which is a fair discount to the market considering its reliance on fuel. Lastly, the FAA grounded all flights in the U.S. on Friday night, disrupting hundreds of flights. At the open Monday morning Delta stock does not seem to be reacting much, which tells you how investors feel about the shutdown (nothing). Risk management: Josh — This isn’t a great setup right now. Fuel has whipsawed Delta all year, as Sean laid out above, and a move back above $90 would give me more confidence in a new entry. Delta spent September and October stuck between $74 and $86. It bottomed at $74 on Oct. 20 and broke out of the range on Nov. 4. The stock ran to $93 within a week, then gave the move back and closed Friday at $86, right on the old ceiling. The 50-day is at $82 and the 200-day is at $78. $90 is where the stock traded for three sessions before Thursday’s drop, so that’s the level to take back first. The $93 high is next, then the $95 to $96 zone that capped the stock in July and August. With RSI at 54, momentum has rolled over from the high 60s it reached on Nov. 4 and Nov. 10. That’s a neutral reading. There’s no stretched condition to work off and no washed-out one to lean on. A push back through $90 would be more convincing with RSI turning up alongside it. Traders can use $80 as their stop. That’s where the stock based in the last days of October before the breakout, and it’s about 7% below Friday’s close, which leaves room for a normal retest of the $86 ceiling. A close below $80 puts Delta back inside the old range with the breakout erased. Investors can anchor to $74, the Oct. 20 low and the bottom of the range. The stock dipped below its 200-day in mid-October and buyers took it right back. A weekly close below $74 and the range has resolved to the downside. Some traders use an order type called a Buy Stop Limit in a situation like DAL. If we think the retaking of $90 would be very bullish (and I do), one way to trade this name would be to place a Buy Stop Limit order in, good til canceled, and let the next breakout attempt be the buy trigger. Yes, you’d be paying up four bucks a share for the stock but you’d avoid sitting in something messier by saving your buying power until then. Not advice, just a thought. DISCLOSURES: (None) All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, or its parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL’S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.Read More

Leave a Reply

Your email address will not be published. Required fields are marked *